

## **INDEX**

*Practical Guide to Transfusion Medicine, 2<sup>nd</sup> ed.*

*Italicized page numbers indicate tables or figures.*

### **A**

- AABB inspections, 478–479
- ABO blood group system, 59–71
  - ABO antibodies, 37, 70–71, 140–141, 285
  - ABO gene, 65–66
  - biochemistry, 61–64
  - chimeric phenotypes, 68–69
  - frequencies of, *61*
  - and H antigen, 62–64, 72, 73
  - in hemolytic disease of the newborn, 71, 283, 285–286
  - and Lewis system, 73, 78–79
  - overview, 59–60
  - phenotypes and genotypes, 60–61
  - physiologic role, 71
  - secretor status, 72, 78–79
  - subgroups, 30–31, 65, 66, 68
  - switching types, 333–334
  - testing for, 28–31, 241, 325, 326
  - typing discrepancies, 30–31, 66, 67, 68–70
- Accreditation, 478–482
- ACD (acid-citrate-dextrose), 14, 15
- ACE (angiotensin-converting enzyme) inhibitors, 165, 429
- Acetylsalicylic acid (ASA), 210, 313, 440
- Acquired B, 68
- Activated partial thromboplastin time (aPTT), 142, 211–214, 215, 305
- Acute chest syndrome (ACS), 295–296
- Acute hemolytic transfusion reactions (AHTR), 148–150, *168*
- Acute myelogenous leukemia (AML), 441
- Acute normovolemic hemodilution (ANH), 229, 244–249, 252, 270–271
- Acute pain crises (APC), 294–295
- Acute respiratory distress syndrome (ARDS), 158–159
- Acute splenic sequestration, 295
- ADAMTS-13, 336–337, 438, 439
- Additive solutions, 3–4, 14–15
- Administration of components
  - blood warmers, 137–138
  - filters, 135–136
  - identification of patient, 133–134
  - infusion time, 134–135
  - intravenous fluids, 137
  - monitoring patients, 138–139
  - needle size, 136–137

- in pediatric patients, 135–136, 139–142
- preparation of patient, 138
- Adsorption procedures, 42–43
- Adult T-cell leukemia/lymphoma (ATL), 180
- Adverse reactions. *See also* Transfusion Reactions; Transfusion-transmitted diseases
  - to autologous donation, 239–241
  - to blood substitutes, 268–269, 274–275
  - reporting, 463–464
- AET (2-aminoethylisothiuronium), 45
- Agglutination
  - column, 45–46
  - grading strength of, 28, 29
- AIDS (acquired immunodeficiency syndrome), 178. *See also* Human immunodeficiency virus
- Air emboli, 249–250
- Albumin, 323–324, 355, 358–360, 428–429
- Allergic transfusion reactions, 155–156, 169, 230
- Alloimmunization
  - in hemolytic disease of the newborn, 282–283
  - to platelets, 309
  - prevention of, in sickle cell disease, 96, 302–303
  - risk of, 328–329
- Alpha<sub>1</sub>-proteinase inhibitor, 409–410
- Alphanate, 365–366, 392
- AlphaNine SD, 376, 393
- Amniocentesis, 287
- Anaphylactic/anaphylactoid transfusion reactions, 156–158, 169
- Anemia. *See also* Sickle cell disease
  - anemia of chronic disease (ACD), 261, 264
  - in cancer patients, 261–263, 264
  - in hemolytic disease of the newborn, 281–282
  - in pure red cell aplasia, 258–259, 264
  - in renal disease, 259–260, 264
  - in surgical patients, 263–264
  - transfusion triggers in, 204–205
- Anesthesia, 301–302, 429–430
- Anti-A, 37, 70, 285
- Anti-A<sub>1</sub>, 30–31, 66, 84
- Anti-A,B, 70, 285
- Anti-B, 37, 70
- Anti-C/c, 96, 99–100, 286, 332
- Anti-Ce/ce, 96, 99
- Anti-D, 94
  - and anti-G, 99–100
  - emergency transfusion with, 332
  - in hemolytic disease of the newborn, 282, 284–285, 286
  - and selection of components, 36
- Anti-Di<sup>a</sup>/Di<sup>b</sup>, 119, 283, 286
- Anti-E/e, 96, 332
- Anti-f (anti-ce), 96, 99
- Anti-Fy<sup>a</sup>/Fy<sup>b</sup>, 113, 283, 286
- Anti-G, 99–100

Anti-H, 74, 75, 84  
Anti-I/i, 84, 91  
Anti-IgA, 157  
Anti-IgG (AHG reagent), 24, 25  
Anti-IH, 84  
Anti-inhibitor coagulant-complex (AICC), 370, 372–373, 393  
Anti-Jk<sup>a</sup>/Jk<sup>b</sup>, 109, 111, 283, 286  
Anti-K/k, 105, 283, 286  
Anti-Le<sup>a</sup>/Le<sup>b</sup>, 80–81, 91  
Anti-Lu<sup>a</sup>/Lu<sup>b</sup>, 116  
Anti-M, 108–109  
Anti-N, 108–109  
Anti-Nf, 91  
Anti-P, 88, 91  
Anti-P<sub>1</sub>, 88  
Anti-PP<sub>1</sub>P<sup>k</sup> (anti-Tj<sup>a</sup>), 88  
Anti-S/s, 109  
Anti-Tj<sup>a</sup>, 88  
Anti-U, 109  
Anti-WARR, 119  
Anti-Wd<sup>a</sup>, 119  
Anti-Wr<sup>a</sup>, 119  
Anti-Xg<sup>a</sup>, 122  
Antibodies. *See also* Antibody detection test; *specific antibodies*  
  autoantibodies, 42–43, 84  
  clinical significance of, 123–124  
  disease association with, 91  
  finding compatible blood with, 122–127  
  HLA, 10, 309–312  
  IgM vs. IgG, 24, 25, 26  
  naturally occurring, 27  
  platelet-specific, 309  
  production of, 23–24, 26–27  
  structure of, 24  
  summary of properties, 128–129  
Antibody detection test, 32–34  
  on autologous blood, 241  
  importance of, 39, 328–329  
  in transfusion emergencies, 325, 326–328  
Antibody elution, 42  
Antibody identification, 34–35  
  adsorption procedures, 42–43  
  antibody elution, 42  
  column agglutination, 45–46  
  panel testing, 34–35, 52–58  
  patient phenotype, 35  
  solid-phase red cell adherence assay, 47–48  
  special techniques for, 43–45  
  time required for, 325  
Antibody titers, 286–287  
Anticoagulant/preservative solutions, 3, 14–15, 237–238, 433

Antifibrinolytic agents, 312

Antigens, blood group. *See also specific blood groups*  
expression of, 23  
frequencies of, 124–127, 303  
gene and gene products, 130–131  
summary of properties, 128–129

Antihuman globulin reagents (AHG), 24, 25, 34, 41

Antithrombin, 383–391, 394

AnWj antigen, 120–121

Apheresis  
blood substitutes in, 274  
collection of hematopoietic progenitor cells, 444–446  
component collection by, 2–3, 442–443  
equipment used for, 425–426  
therapeutic  
  cytapheresis, 426, 441–442  
  extracorporeal volume in, 430  
  follow-up testing in, 431  
  immunoabsorption, 444  
  informed consent in, 431  
  medication history in, 429–430  
  patient history in, 429–430  
  percentage of constituents removed in, 430–431  
  photopheresis, 444  
  plasma exchange, 339, 426, 427, 437–441  
  plasmapheresis, 425–426, 434–437  
  replacement fluids in, 428–429  
  risks of, 431–433  
  uses of, 426–427, 449–451  
  vascular access in, 428

Apheresis Platelets, 3, 9, 20, 442

Aplastic crises (in sickle cell disease), 294

Argatroban, 386–388, 394

Arixtra, 389–391, 394

Artificial oxygen carriers. *See* Blood substitutes

ASPEN syndrome, 297

Aspirin, 210, 313, 440

Audits, transfusion and wastage, 468–470, 471–473

Autoantibodies  
adsorption of, 42–43  
biphasic hemolysin, 88  
cold, 81–82, 84

Autocontrol, 34–35, 41, 57–58

Autoimmune hemolytic anemia, 84

Autologous blood. *See also specific collection techniques*  
acute normovolemic hemodilution, 244–249, 270–271  
general concepts of, 227–228  
handling, storage and expiration of, 252  
indications for, 229  
intraoperative blood recovery, 249–251, 253  
postoperative blood recovery, 253–255

preoperative donation, 228–244  
Autonomy, 483

## B

B antigen, acquired, 68  
B(A) phenotype, 68  
Babesiosis, 2  
Bacterial contamination  
  of autologous blood, 231, 235, 244  
  of platelets, 2–3, 4–5, 17, 163–164  
  of Red Blood Cells, 164  
  septic transfusion reaction, 163–165, 170, 230–231, 235  
Beneficence, 483, 484  
BeneFix, 377–378, 393  
Bethesda units (BU), 366  
Bg (Bennett Goodspeed) antigens, 117  
Bilirubin in hemolytic disease of the newborn, 281–282, 287–288, 291  
Blood collection, 2–3, 442–443  
Blood components. *See* Components, blood  
Blood groups and collections. *See also specific blood groups and collections*  
  antigen frequencies of, 124–127, 303  
  disease associations with, 91  
  gene and gene products, 130–131  
  null phenotypes, 132  
  summary of properties of, 128–129  
Blood loss, acute. *See* Hemorrhage  
Blood samples, 40, 133–134  
Blood shortages, 275, 345–347, 482, 484  
Blood substitutes, 265–275  
  adverse effects of, 268–269, 274–275  
  bovine-source polymerized hemoglobin, 270, 271–273, 274–275  
  in cardiopulmonary bypass, 274  
  in elective surgery, 270–272  
  emergency uses of, 267–270  
  hemoglobin-based oxygen carriers, 266–267  
  human-source polymerized hemoglobin, 267–270  
  perfluorocarbons, 265–266, 271  
  to reduce blood viscosity, 273–274  
Blood usage committee, 467–468, 471–473  
Blood viscosity  
  hyperviscosity and apheresis, 436–437  
  reducing with blood substitutes, 273–274  
  in sickle cell disease, 273, 294  
Blood warmers, 137–138, 307, 433  
Bombay phenotype, 71–72, 74, 75  
Bovine-source polymerized hemoglobin, 270, 271–273, 274–275  
Budget, annual, 476–478

## C

C/c antigens, 94–95, 99  
Calcium, 307

Cancer, 261–263, 264  
CAP inspections, 479–480  
Cardiac surgery, 210–211, 274  
Cartwright blood group, 117  
Ce, CE, cE, and ce antigens, 99, 100  
Ch antigen, 117  
Chagas' disease, 1, 186–187  
Change management, 466  
Chemical treatments, 44, 45  
Chemotherapy-related anemia, 261–263, 264  
Chido/Rodgers blood group, 117–118  
Chloroquine, 45  
Chorionic villus sampling (CVS), 287  
Chronic inflammatory demyelinating polyneuropathy (CIDP), 434–435  
Chronic myelogenous leukemia (CML), 441  
Circulatory overload, 170  
Citrate toxicity, 433  
Co<sup>a</sup>/Co<sup>b</sup> antigens, 118  
Coagulation factor concentrates. *See* Factor concentrates; *specific coagulation factors*  
Coagulopathy, 305–307  
Cold autoantibodies, 81–82, 84  
Cold autoimmune hemolytic anemia, 84  
Colloidal solutions, 323–324  
Colton blood group, 118  
Column agglutination, 45–46  
Compatibility testing  
    abbreviated, in emergencies, 325–330, 333  
    ABO typing, 28–31  
    adsorption procedures, 42–43  
    antibody detection, 32–34, 39  
    antibody elution, 42  
    antibody identification, 34–35, 52–58  
    of autologous blood, 241  
    chemical treatments, 44, 45  
    column agglutination, 45–46  
    crossmatch, 38–40  
    direct antiglobulin test, 33, 35, 41–42, 58  
    enzyme treatment, 43–44  
    identification of samples for, 133–134  
    neutralizations, 43–44  
    for platelets and plasma, 48–49  
    repeat testing, 40  
    Rh typing, 31–32  
    solid-phase red cell adherence assay, 47–48  
    time required for, 325  
    type and screen, 27  
Components, blood. *See also specific components*  
    administration of, 133–142  
    collection by apheresis, 2–3, 442–443  
    for neonates, 140–142  
    preparation of, 1–11

- selection of, 35–38, 122–127
- shortages of, 275, 345–347, 482, 484
- storage of, 13–21
- usage and wastage audits of, 468–470, 471–473

Computer crossmatch, 39–40

Consent, informed, 431

Consultations, automatic, 457–459

Coombs reagent, 24, 25, 41

Cordocentesis, 287

Corrected count increment (CCI), 308, 312

CPD (citrate-phosphate-dextrose), 3, 14, 15

CPDA (citrate-phosphate-dextrose-adenine), 3, 14, 15

Creutzfeldt-Jakob disease/variant (CJD/vCJD), 188–190, 192

- donor screening for, 2
- and leukocyte reduction, 10, 189–190, 219–220
- transmission by plasma derivatives, 7, 356–357

Cromer blood group, 118

Crossmatching, 38–40

- autologous blood, 241
- electronic, 39–40
- emergency, 325, 326–327
- granulocytes, 38
- immediate-spin, 38–39, 326, 328
- platelets, 38, 309, 310

Cryo-poor plasma, 5–6, 20, 440

Cryoglobulinemia, 436

Cryoprecipitated AHF (Cryo)

- ABO compatibility, 37, 38, 48
- dosage, 215
- indications, 214–215, 217, 363, 392
- in massive transfusion, 306
- preparation, 5–6, 9
- thawing and storage, 6, 9, 18, 20, 21

Cryopreservatives, 15–16

Crystalloid solutions, 323–324

Cytapheresis

- for allogeneic blood collection, 2–3, 442–443
- therapeutic, 426, 441–442

Cytomegalovirus (CMV), 182–184

- and leukocyte reduction, 10, 182–183, 220–221
- and neonatal transfusion, 142

## **D**

D antigen, 31–32, 93–94, 97–98

- partial D, 98–99
- weak D, 32, 98–99

Delayed hemolytic transfusion reactions (DHTR), 150, 153, 168, 303–304

Desmopressin (DDAVP), 314

Di<sup>a</sup>/Di<sup>b</sup> antigens, 118–119

Dialysis, 259–260

Diego blood group system, 118–119, 283, 286

2, 3-diphosphoglycerate (2, 3-DPG), 14  
Direct antiglobulin test (DAT), 33, 35, 41–42, 58, 290  
Dithiothreitol, 45  
Dombrock blood group, 119  
Donor qualifications  
    in acute normovolemic hemodilution, 246–247  
    for blood donation, 1–2  
    for intraoperative blood recovery, 251  
    for postoperative blood recovery, 254  
    for preoperative blood donation, 232–236, 238  
    and transfusion-related acute lung injury, 160–161  
Donor reactions, 239–241  
Doppler flow velocity studies, 287, 288  
Drugs. *See* Medications  
D<sup>u</sup> (weak D), 32, 98–99  
Duffy blood group system, 111–114, 283, 286  
Dysproteinemia, 436–437

## **E**

E/e antigens, 94–95, 99  
Electronic crossmatch, 39–40  
Elution, antibody, 42  
Emergency procedures  
    in acute blood loss, 321–333  
    blood substitutes in, 267–270  
    communication in, 330  
    compatibility testing in, 325–330, 333  
    component shortages, 345–347  
    concepts of, 346  
    incompatible transfusions, 330–331  
    in massive transfusion, 333–334  
    switching blood types in, 333–334  
    transfusion of patient with Rh antibodies, 332–333  
    urgent plasma transfusions, 338–345  
    urgent platelet transfusions, 335–338  
    urgent red cell transfusions, 324–325  
    use of crystalloid solutions in, 323–324  
Enzymatic conversion of red cells, 275–277  
Enzymes, proteolytic, 43–44  
Equipment  
    apheresis, 425–426  
    for blood storage, 21  
    requests for, 477–478  
Errors  
    ABO mismatch, 70–71, 231, 329–330  
    mislabeled samples, 133–134  
    in patient identification, 133  
    reporting, 462  
Erythrocytapheresis, 296–297, 426  
Erythropoietin (EPO)  
    human, 257–258, 264

- recombinant, 257–264
  - in anemia of chronic disease, 261
  - in malignant disease, 261–263
  - in perioperative period, 263–264
  - in preoperative autologous blood donation, 231–232, 263
  - and pure red cell aplasia, 258–259
  - in renal disease, 259–261
  - side effects of, 260–261

Ethics, in transfusion service management, 482–485

Exchange transfusion, 291, 296, 297

Extracorporeal volume, 430

## **F**

f antigen, 99, 100

Factor VIIa, recombinant, 378–381, 394

- for heparin reversal, 345

- for inhibitors to Factors VIII and IX, 373

- for massive transfusion, 307–308

- for platelet refractoriness, 312

- for warfarin reversal, 341, 342, 343–344

Factor VIII concentrates, 360–369, 392–393

- dosage, 362–363

- guidelines for therapy, 361

- high-purity, recombinant, 367–369

- intermediate-purity, 364–367

- low-purity, 363

- porcine, 373

- preparation, 5–6, 353, 362

- viral content, 355

Factor VIII inhibitors, 372–373, 378, 379

Factor IX concentrates, 374–378, 393

- dosage, 374, 375–376

- Factor IX complex concentrates, 339, 340–341, 342–343, 373, 376–377

- high-purity recombinant, 377–378

- indications, 374–375

- viral content, 355

Factor IX inhibitors, 372–373, 378, 379

Factor concentrates, 392–394. *See also specific factor concentrates*

- infectious disease transmission with, 7, 355–357

- preparation of, 6–7, 353–355

Fatalities, transfusion-related

- due to bacterial contamination, 164

- due to transfusion errors, 133

- due to transfusion-related acute lung injury, 159–160, 161

- reporting, 464

FDA inspections, 479, 481

Febrile (nonhemolytic) transfusion reactions (FNHTR), 10, 154–155, 169, 220, 230

FEIBA VH, 370, 372–373, 393

Fetal alloimmune thrombocytopenia (FAIT), 291–293, 336

Fetal screen test (rosette test), 285, 320

Fetomaternal hemorrhage (FMH), 282–283, 285

Fibrin sealant, 215, 409  
Fibrinogen  
    Cryo as replacement for, 214–215, 306  
    in massive transfusion, 305, 306  
Filters, 135–136, 219, 220  
Fisher-Race nomenclature, 95–96  
Flebogamma, 396–397, 399  
Fluids  
    intravenous, 137  
    replacement, in apheresis, 428–429  
Free fetal DNA (ffDNA), 287  
Fresh frozen plasma (FFP)  
    ABO compatibility of, 36, 37, 38, 48  
    and heparin reversal, 344–345  
    indications for, 211–214, 217  
    for neonates, 141, 142  
    preparation of, 5–6, 9, 13  
    thawing and storage of, 6, 9, 17–18, 20  
    timing and dose of, 213  
    urgent transfusion of, 338–345  
    use in massive transfusion, 306  
    in warfarin reversal, 339, 340–341, 342, 343, 344  
Frozen red blood cells, 15–16, 19  
Fy<sup>a</sup>/Fy<sup>b</sup>/Fy3/Fy5 antigens, 111, 112–113

## G

G antigen, 99–100  
GamaSTAN SD, 395–396, 398  
Gamma irradiation. *See* Irradiation  
Gammagard SD, 396–397, 399  
Gamunex, 396–397, 399  
Gel (column) agglutination, 45–46  
Genes and gene products, 130–131  
Gerbich blood group, 119–120  
Gil blood group, 120  
GLOB collection, 85–89  
Glycerol, 15–16  
Goodpasture's syndrome, 435–436  
GPIIb/IIIa inhibitors, 211, 313–314  
Graft-vs-host disease, transfusion associated, 162–163, 171, 221–222  
Gram's stain, 165  
Granulocyte colony-stimulating factor (G-CSF), 410–411  
Granulocyte/macrophage colony-stimulating factor (GM-CSF), 410–411  
Granulocytes  
    ABO compatibility of, 37, 49  
    collection by apheresis, 443  
    crossmatching, 38  
    indications for, 215, 218–219  
Guillain-Barré syndrome (GBS), 434–435  
Gy<sup>a</sup> antigen, 119

## H

- H blood group system, 71–75
  - and ABO antigens, 62–64, 72, 73
  - antibodies, 74, 75, 84
  - biochemistry and synthesis, 72, 73
  - molecular biology, 72
  - null phenotypes, 74–75
  - physiologic role, 75
- Haptoglobin deficiency, 157
- HBOC-201(Hemopure), 270, 271–273, 274–275
- Hematocrit, transfusion triggers, 204
- Hematomas, 240–241
- Hematopoietic factors, recombinant
  - erythropoietin, 231–232, 257–264
  - granulocyte/macrophage colony-stimulating factors, 410–411
  - interleukin-11, 411–412
  - thrombopoietin, 412–414
- Hematopoietic progenitor cells (HPCs)
  - collection by apheresis, 444–446
  - transplantation of, 68–69
- Hemodilution. *See* Acute normovolemic hemodilution
- Hemofil M, 366–367, 392
- Hemoglobin
  - bovine-source polymerized, 270, 271–272, 274
  - in cancer patients, 262–263, 264
  - fetal, 288
  - human-source polymerized, 267–270
  - recombinant, 267–274
  - in renal failure patients, 259–260, 264
  - S, 294, 301–302
  - transfusion triggers, 142, 204–207
- Hemoglobin-based oxygen carriers (HBOC), 266–267
- Hemolytic anemia, cold autoimmune, 84
- Hemolytic disease of the fetus and newborn (HDFN), 281–291
  - ABO-associated, 71, 283, 285–286
  - alloimmunization in, 282–286
  - due to other antibodies, 286
  - management of newborn, 289–291
  - management of sensitized pregnancy, 286–289
  - Rh-associated, 101–102, 284–285
- Hemolytic transfusion reactions (HTR)
  - acute, 148–150, 168
  - delayed, 150, 153, 168, 303–304
  - due to ABO mismatch, 70–71, 231
- Hemolytic uremic syndrome (HUS), 439
- Hemophilia, 360–361
- Hemorrhage
  - in apheresis, 432
  - classification of, 321–323
  - compatibility testing for, 325–330
  - crystalloid solutions in, 322, 333–334

- fetomaternal, 282–283, 285
- massive, transfusion for, 305–308, 333–334
- RBC transfusion in, 324–325
- use of blood substitutes in, 267

Heparin cofactor. *See* Antithrombin

Heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), 387–388

Heparin-induced thrombocytopenia (HIT), 314, 337–338

Heparin reversal, 344–345

Hepatitis

- A, 172, 173–174
- B, 172–173, 174–176
- C, 172–173, 176–178
- D, 172, 173, 178
- E, 172
- G, 178
- in plasma derivatives, 355, 356
- screening donors for, 1, 241–242

HLA system, 10, 117, 309–312

HPA-1a platelet antigen, 166–167, 292, 309, 312

HPC-A (hematopoietic progenitor cell) collection, 444–446

HTLV-associated myelopathy (HAM), 180, 181

Human herpesvirus-8, 185

Human immunodeficiency virus (HIV), 178–180

- and cytomegalovirus, 183–184
- in plasma derivatives, 355, 356
- screening donors for, 1, 2, 242

Human platelet antigen HPA-1a, 166–167, 292, 312

Human-source polymerized hemoglobin, 267–270

Human T-cell lymphotropic virus (HTLV), 1, 180–181, 242

Humate-P, 364–365, 369–370, 392, 393

Hy antigen, 119

Hyperbilirubinemia, 281–282, 291

Hyperimmune globulins, 397, 400–409

Hyperviscosity syndromes, 436–437

Hypocalcemia, 307

Hypotensive reactions, 165–166, 358

Hypothermia, 307

Hypovolemic reactions, 240, 323

## I

I blood group system, 81–84, 91

Identification of patient, 133–134, 231

Idiopathic thrombocytopenic purpura (ITP), 313, 335, 407, 408

IgA deficiency, 156–157

IgG/IgM antibodies, 24, 25, 26

Immune globulins, 391, 395–397, 398–399

- hyperimmune globulins, 397, 400–409
- intramuscular (IGIM), 395–396
- intravenous (IVIG), 292, 335, 396–397, 434
- Rh immune globulin, 400–409
- subcutaneous, 395

- viral content of, 355
- Immune thrombocytopenic purpura (ITP), 313, 335, 407, 408
- Immunoabsorption column apheresis, 444
- Indian blood group, 120–121
- Indirect antiglobulin test (IAT), 33. *See also* Antibody detection test
- Infection, and apheresis, 432
- Infectious diseases. *See also specific diseases*
  - reducing with leukocyte reduction, 10, 221–222
  - testing for, 1–2, 241–242
  - transmission by plasma derivatives, 7, 355–357
- Informed consent, 431
- Infusion sets, 135–136
- Infusion time, 134–135
- Inspections and accreditation, 478–482
- Interleukin-11, recombinant, 411–412
- International normalized ratio (INR), 212–213
- Intraoperative blood recovery, 229, 249–251, 252, 253
- Intrauterine transfusions, 288–289
- Intravenous fluids, 137
- Intravenous immune globulin (IVIG), 292, 335, 396–397, 434
- Iron supplementation, 236–237, 258
- Irradiation
  - of components for neonates, 142
  - of granulocytes, 163, 219
  - indications for use of, 163, 221–222
- Ishikawa diagram, 463

## **J**

- Jk<sup>a</sup>/Jk<sup>b</sup> antigens, 109–111
- Jk<sub>null</sub> phenotype, 109, 110–111
- JMH (John Milton Hagen) blood group, 121
- Jo<sup>a</sup> antigen, 119
- Js<sup>a</sup>/Js<sup>b</sup> antigens, 102, 103
- Jumbo plasma, 442
- Justice, 483, 484

## **K**

- Kaposi's sarcoma, 185
- Kell blood group system, 102–105, 283, 286
- Kidd blood group system, 109–111, 283, 286
- Kleihauer-Betke test, 285, 320
- Knops blood group, 121
- Koate-DVI, 365, 392
- Kogenate FS, 367–368, 392
- Kp<sup>a</sup>/Kp<sup>b</sup> antigens, 102, 103
- K<sub>x</sub> blood group, 102, 103

## **L**

- Labeling
  - autologous blood, 242–243
  - blood samples, 133–134

Lactate dehydrogenase (LDH), 431  
Lactated Ringer's solution, 137, 323, 325  
Le<sup>a</sup>/Le<sup>b</sup> antigens, 75–76, 77, 78–80  
Leukapheresis, 441–442  
Leukemia, 441–442  
Leukocyte reduction

- during apheresis, 442–443
- and Creutzfeldt-Jakob disease, 10, 189–190, 192, 219–220
- and cytomegalovirus infection, 10, 182–183, 220–221
- and febrile transfusion reactions, 154, 220
- filters for, 135, 136, 219–220
- hypotension associated with, 165–166
- indications for, 219–221
- prestorage, 2, 7, 10–11, 220, 443
- and transfusion-related immunomodulation, 221
- universal, 7, 10, 189, 219

Leukostasis, 441–442  
Lewis blood group system, 73, 75–81, 91  
Liley curve, 288  
Liquid Plasma, 18  
Liver failure, 306–307, 440–441  
LKE (Luke) antigen, 85, 87, 89  
Look-back, 465–466  
Low-volume units, 3  
Lutheran blood group system, 114–116  
LW (Landsteiner-Wiener) blood group, 121

## M

Magnetic resonance angiography (MRA), 299–300  
Malaria, 186  
Malignancies, rhEPO in, 261–263  
Management of transfusion service

- automatic consultations, 457–459
- blood usage/transfusion committee, 467–468, 471–473
- budgets and costs, 476–478
- change management, 466
- clinical rounds, 459–460
- ethical considerations in, 482–485
- inspections and accreditation, 478–482
- maximum surgical blood order schedule, 232–233, 470, 474–475
- overview of, 454–457
- quality assurance, 462–466
- staffing plans, 475
- transfusion and wastage audits, 468–470, 471–473
- transfusion service rounds, 459, 460

Market withdrawal, 465  
Massive transfusion, 305–308

- coagulopathy in, 305–307
- compatibility testing in, 333
- ethical dilemmas in, 482, 483–484
- hypocalcemia in, 307

- hypothermia in, 307
- switching blood types in, 333–334
- Maximum surgical blood order schedule (MSBOS), 232–233, 470, 474–475
- MCA Doppler flow rates, 287, 288
- McLeod phenotype, 102, 103–104, 105
- 2-ME (2-mercaptoethanol), 45
- Medical director, duties of, 453–456. *See also* Management of transfusion service
- Medical history, 1, 2, 237, 238, 429–430
- Medications
  - affecting platelet function, 210, 313–314, 440
  - infusion of, with transfusions, 137
  - patient history of, 429–430
  - pretransfusion, 138, 331
  - for transfusion reactions, 151–152, 154–155
- Megakaryocyte growth and development factor, recombinant, 413
- MER2 antigen, 122
- Microaggregate filters, 135
- MNS blood group system, 105–109, 283, 286
- Mpl* ligand, 412–413
- Multiple myeloma, 436, 437
- Myasthenia gravis (MG), 435

## N

- N antigen, 105–108
- Needle sizes, 136–137
- Neonatal alloimmune thrombocytopenia (NAIT), 291–293, 336
- Neonates
  - administration of components in, 135–136, 139–142
  - cytomegalovirus in, 142, 183
  - doses and expected response to transfusion, 141
  - fetal alloimmune thrombocytopenia, 291–293, 336
  - hemolytic disease of the newborn, 281–291
  - selection of components for, 140–142
- Nerve injuries in donors, 241
- Neutralizations, 43–44
- Neutropenia, 215, 218
- Nonmaleficence, 483, 484–485
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 210, 313
- NovoSeven, 378–381, 394
- Nucleic acid testing (NAT), 1, 2
  - for HBV, 175–176
  - for HCV, 177
  - for HIV, 177, 179
  - for West Nile virus, 184–185
- Null phenotypes, 132

## O

- OK blood group, 122
- Orders, transfusion, 457–459, 468–470
- Oxygen therapeutics. *See* Blood substitutes

## P

- P blood group system, 85–89, 91
- Panagglutinins, 42
- Para-Bombay phenotype, 71–72, 74–75
- Parasitic infections, 186–188
- Pareto analysis, 462–463
- Paroxysmal cold hemoglobinuria (PCH), 88
- Partial D, 98–99
- Partial thromboplastin time (PTT), 142, 211–214, 215, 305
- Parvovirus B19, 89, 356
- Patients
  - eligibility for autologous donation, 232–236, 246–247, 251, 254
  - identification, 133–134, 231
  - medical history, 1, 2, 237, 238, 429–430
  - monitoring during blood administration, 138–139
  - pretransfusion preparation, 138
- Pediatric patients. *See also* Neonates
  - autologous donations from, 234, 235
  - blood administration in, 135–136, 139–142
  - needle sizes for, 136–137
- PEG-treated RBCs, 275–277
- Percutaneous umbilical blood sampling (PUBS), 287, 288–289
- Perfluorocarbons (PFCs), 265–266, 271
- Personnel, transfusion service, 475, 477–478
- Phenotypes. *See also specific blood groups*
  - fetal, 287
  - null, 132
  - patient, 35
- Photopheresis, 444
- Phototherapy, 291
- P<sup>k</sup> antigen, 85–86, 89
- Pl<sup>A1</sup> platelet antigen. *See* HPA-1a platelet antigen
- Plasma. *See also* Fresh Frozen Plasma
  - ABO compatibility of, 36, 37, 38, 48
  - collection of, by apheresis, 442
  - Cryoprecipitate Reduced (cryo-poor), 5–6, 20, 440
  - Frozen Within 24 Hours After Phlebotomy, 5, 18, 20
  - jumbo, 442
  - Liquid, 18
    - as replacement fluid in apheresis, 429
  - solvent/detergent-treated, 214
  - Thawed, 18
    - urgent transfusion of, 338–345
- Plasma derivatives, 351–410. *See also specific plasma derivatives*
  - overview of, 351–353, 392–394
  - preparation of, 6–7, 353–355
  - viral content of, 355–357
- Plasma exchange, 339, 426, 427, 437–441. *See also* Apheresis
- Plasma protein fraction (PPF), 355, 357–358, 360
- Plasmapheresis, therapeutic, 425–426, 434–437. *See also* Apheresis
- Platelet inhibitors, 211, 313–314

## Platelets

- ABO/Rh compatibility of, 37–38, 48–49
  - antibodies to, 309
  - antigen HPA-1a, 166–167, 292, 309, 312
  - apheresis, 3, 9, 20, 442
  - bacterial contamination of, 2–3, 4–5, 17, 163–164
  - corrected count increment, 308, 312
  - crossmatching, 38, 309, 310
  - dysfunction of, 209–210, 313–314
  - in heparin-induced thrombocytopenia, 314, 337–338
  - HLA-matched, 310–312
  - in idiopathic thrombocytopenic purpura, 313, 335
  - indications for transfusion of, 207–211, 216
  - leukocyte reduced, 443
  - in neonatal alloimmune thrombocytopenia, 293, 336
  - for neonates, 141
  - posttransfusion counts, 305, 312
  - preparation of, 4–5, 8–9
  - refractoriness, 10, 308–313
  - shortages of, 345–347
  - storage of, 4–5, 8–9, 16–17, 19–20
  - urgent transfusion of, 335–338
- Polyethylene glycol (PEG)-treated RBCs, 275–277
- Polymerized human stroma-free hemoglobin (PolyHeme/Poly SFH-P), 267–271, 274
- Postoperative blood recovery, 229, 252, 253–255
- Posttransfusion purpura (PTP), 166–167, 171, 312–313, 437
- Potassium, 141
- Precautionary principle, 484–485
- Pregnancy
- autologous donation in, 234
  - sensitized, management of, 286–289
  - in sickle cell disease, 300–301
- Premedication. *See* Medications
- Preoperative autologous blood donation (PAD), 228–244
- adverse donor reactions, 239–241
  - benefits of, 228, 230
  - indications for, 229
  - labeling, 242–243
  - limitations and risks, 230–232
  - patient eligibility, 232–236, 238
  - procedure, 236–239
  - quality control, 244
  - recombinant erythropoietin in, 231–232, 263
  - storage, 242–243
  - testing, 241–242
  - transfusion trigger, 243–244
- Pretransfusion testing. *See* Compatibility testing
- Priapism, 296–297
- Procedures, reviewing, 464
- Profilnine SD, 376–377, 393
- Protein C, 381–383, 394

Proteolytic enzyme treatments, 43–44  
Prothrombin complex concentrates (PCC), 339, 340–341, 342–343, 374, 376–377  
Prothrombin time (PT), 142, 211–214, 215, 305  
Pulmonary edema. *See* Transfusion-related acute lung injury  
Pure red cell aplasia (PRCA), 258–259, 264

## Q

Quality control/assurance  
  of autologous blood, 244, 248–249, 251, 253, 254–255  
  in management of blood bank, 462–466

## R

RAPH blood group, 122  
Rationing blood, 482, 484  
Recalls, 465  
Recombinant coagulation factors. *See specific coagulation factors*  
Recombinant erythropoietin. *See* Erythropoietin  
Recombinant hematopoietic factors. *See* Hematopoietic factors, recombinant  
Recombinant hemoglobin, 267–274  
Recombinate, 368–369, 393  
Red blood cells (RBCs)  
  aliquots of, 141–142  
  bacterial contamination of, 164  
  collection of, by apheresis, 252, 442  
  enzymatic conversion of, 275–277  
  for exchange transfusion, 291  
  frozen, 15–16, 19  
  giving Rh-positive RBCs to Rh-negative patients, 333–334  
  indications for transfusion of, 204–207, 216  
  for intrauterine transfusion, 288, 289  
  leukocyte reduced, 443  
  for neonates, 140–142  
  preparation of, 3–4, 8  
  rejuvenating solutions for, 15  
  selection of, 35–37, 122–127  
  shortages of, 275, 345–347, 482, 484  
  storage of, 8, 14–16, 19  
  uncrossmatched, 327–328  
  urgent transfusion of, 324–325  
Red cell exchange, 296–297, 426  
Refacto, 369, 393  
Rejuvenating solutions, 15  
Renal disease, recombinant erythropoietin in, 258–261, 264  
Repeat testing, 40  
Retroviral infections, 178–181  
Rg antigen, 117  
Rh blood group system, 93–102  
  antibodies, 101–102, 332–333  
  biochemistry and molecular biology of, 97  
  C/c antigens, 99  
  compound antigens, 99, 100

- E/e antigens, 99
- G antigen, 99–100
- haplotype frequencies, 95
- and hemolytic disease of the newborn, 101–102, 284–285
- nomenclature, 95, 96
- phenotypes, 94–96
- physiologic role of, 102
- positivity and negativity, 97–98
- Rh<sub>null</sub> phenotype, 100–101
- and selection of components, 36
- switching types, 333–334
- typing for, 31–32, 241, 287
- weak D, partial D, 32, 98–99
- Rh Immune Globulin (RhIG), 400–409
  - dosage/timing, 401, 402–405, 406, 407–409
  - indications for, 402–405
  - to prevent hemolytic disease of the newborn, 102, 284–285, 286
  - Rh IVIG, 407–409
  - for Rh-negative patients receiving Rh-positive components, 38, 49, 333–334
  - viral content of, 355

#### Risks

- of apheresis, 431–433
- of intraoperative blood recovery, 249–250
- of preoperative donation, 230–232
- of transfusion, 172, 191

Rituximab, 440

Rodgers blood group, 117–118

Root cause analysis (RCA), 462–463

Rosette test (fetal screen test), 285, 320

Rounds, blood bank and clinical, 459–460

## S

S/s antigens, 105–108

Saline, normal, 428–429

Scianna blood group, 122

Secretor genes, 72, 78–79

Seizures, in donors, 240

Sentinel events, 463–464

Septic transfusion reactions, 163–165, 170, 230–231, 235

Shock, hypovolemic, 323

Sickle cell disease (SCD), 293–305

- acute chest syndrome (ACS), 295–296

- acute pain crisis (APC), 294–295

- acute splenic sequestration, 295

- aplastic crisis, 294

- delayed hemolytic transfusion in, 303–304

- hyperhemolysis syndrome, 304

- hypertransfusion protocol in, 96

- indications for transfusion in, 204, 293–297

- pregnancy in, 300–301

- prevention of alloimmunization in, 96, 302–303

- priapism, 296–297
- stroke in, 297–300
- surgery/anesthesia in, 301–302
- use of blood substitutes in, 267, 273

Solid-phase red cell adherence assay (SPRCA), 47–48

Solutions

- additive, 3–4, 14–15
- anticoagulant/preservative solutions, 3, 14–15, 237–238, 433
- in blood administration, 137, 324–325
- colloidal, 323–324
- crystalloid, 323–324, 325
- rejuvenating, 15

Solvent-detergent-treated (SD) plasma, 214

Splenic sequestration, acute, 295

Staffing of transfusion service, 475, 477–478

Standard operating procedures (SOPs), 464

Storage. *See also specific components*

- of autologous blood, 242–243, 252, 254
- of blood components, 13–21
- equipment for, 21
- of pretransfusion samples, 40

Stroke, 297–300

Surgery

- autologous blood for, 229
- blood substitutes in, 267, 270–272, 274
- fibrin sealant in, 215, 409
- Fresh Frozen Plasma in, 211–214
- maximum or standard blood order schedule (MSBOS), 232–233, 470, 474–475
- Platelets in, 210–211
- recombinant erythropoietin in, 263–264
- in sickle cell disease, 301–302

Suxamethonium anesthesia, 429–430

Switching blood types, 333–334

Syphilis, 1, 188, 242

## T

Thawed Plasma, 18

Thawing frozen components, 6

The Joint Commission (TJC)

- inspections, 479, 480–481
- reporting sentinel events to, 463–464

Therapeutic apheresis. *See Apheresis*

Thrombate III, 385–386, 394

Thrombocytopenia

- heparin-induced, 314, 337–338
- heparin-induced and thrombosis syndrome, 387–388
- idiopathic thrombocytopenic purpura, 313, 335, 407, 408
- neonatal/fetal alloimmune, 291–293, 336
- posttransfusion purpura, 166–167, 171, 312–313, 437
- thrombotic thrombocytopenic purpura, 336–337, 339, 438–440
- urgent transfusion for, 335–338

Thrombopoietin (TPO), recombinant, 412–414

Thrombotic thrombocytopenic purpura (TTP), 336–337, 339, 438–440

Titers, antibody, 286–287

Transcranial Doppler ultrasound (TCD), 298, 299

Transfusion-associated graft-vs-host disease (TA-GVHD), 162–163, *171*, 221–222

Transfusion committee, 467–468

Transfusion reactions

- acute hemolytic, 148–150
- allergic (urticarial), 155–156, 230
- anaphylactoid/anaphylactic, 156–158
- from autologous blood, 230–231
- delayed hemolytic, 150, 153, 303–304
- drugs and dosages for, *151–152*
- evaluation of, 139, 147–167
- febrile (nonhemolytic), 10, 154–155, 220, 230
- monitoring patient for, 139
- posttransfusion purpura (PTP), 166–167, 312–313, 437
- primary hypotensive, 165–166
- reporting, 139, 146–148, *461*, 463–464
- review of, 459–460, *461*
- risks of, *172*
- septic (bacterial contamination), 163–165, 230–231, 235
- signs and symptoms of, 145–146
- summary of, *168–171*
- transfusion-associated graft-vs-host disease, 162–163, 221–222
- transfusion-related acute lung injury, 158–162
- types of, *149*

Transfusion-related acute lung injury (TRALI), 158–162, *170*

Transfusion-related immunomodulation (TRIM), 221

Transfusion service physician, duties of, 453–456. *See also* Management of transfusion service

Transfusion-transmitted diseases (TTDs)

- Chagas' disease, 186–187
- Creutzfeldt-Jakob disease, 7, 10, 188–190, 192, 219–220, 356–357
- cytomegalovirus, 10, 142, 182–184, 220–221
- examples of, *173*
- hepatitis, 172–178, 355, 356
- human herpesvirus-8, 185
- human immunodeficiency virus, 178–180, 242, 355, 356
- human T-cell lymphotropic virus, 180–181, 242
- malaria, 186
- Parvovirus B19, 89, 356
- risks of, *191*
- screening donors for, 1–2
- syphilis, 188, 242
- TT virus, 355–356
- West Nile virus, 184–185

Transfusion triggers

- for autologous blood, 243–244, 251, 254
- Cryoprecipitated AHF, 214–215
- for Fresh Frozen Plasma, 211–214
- for Granulocytes, 215, 218–219

- in massive transfusion, 306
- for Platelets, 207–211
- for Red Blood Cells, 204–207, 216
- summary of, 216–217

Transfusions. *See also* Administration of components; *specific components*

- audits of, 468–470, 471–473
- exchange, 291, 296, 297
- incompatible, 330–331
- indications for, 203–204
- intrauterine, 288–289
- of irradiated components, 221–222
- of leukocyte-reduced components, 219–221
- massive, 305–308, 333–334, 482, 483–484
- neonatal, 135, 139–142
- reviewing orders for, 457–459, 468–470
- risks of, 191

Transplantation, and cytomegalovirus, 183

Trauma, 267–268

Tropical spastic paraparesis (HTLV-associated myelopathy), 180, 181

TT virus, 355–356

Type and screen, 27. *See also* Compatibility testing

## U

- U antigen, 105, 107
- Uremic platelet dysfunction, 314
- Urticarial transfusion reactions, 155–156, 169, 230

## V

- Variant Creutzfeldt-Jakob disease (vCJD), 188, 189–190, 192
  - donor screening for, 2
  - leukocyte reduction and reduced risk of, 10, 189–190, 219–220
  - transmission by plasma derivatives, 7, 356–357
- Vascular access, in apheresis, 428
- Vasovagal reactions, 239–240
- Venous thromboembolism (VTE), 389–390
- Virus inactivation, 7, 214, 354–355
- Viruses. *See also* Transfusion-transmitted diseases
  - in plasma derivatives, 7, 355–357
  - reducing with leukocyte reduction, 10, 221–222
  - screening for, 1–2
- Viscosity. *See* Blood viscosity
- Vital signs, 138
- Vitamin K<sub>1</sub>, 339, 340–341, 342
- Vivaglobin, 395, 398
- Volume
  - of autologous blood collected, 237–238, 248
  - of blood collected, 3
  - extracorporeal, 430
  - volume exchange in apheresis, 430–431
- von Willebrand disease, 369–370, 371
- Von Willebrand factor concentrate, 353, 369–370, 393

## **W**

Waldenstrom's macroglobulinemia, 436–437

Warfarin reversal, 339–344

Warming blood, 137–138, 307, 433

Wastage of components, 468–470, 473

Weak D, 32, 98–99

West Nile virus (WNV), 2, 184–185

Whole blood (WB)

    ABO compatibility of, 36, 48

    collection of, 2–3, 8

Wiener nomenclature, 95–96

Wr<sup>a</sup>/Wr<sup>b</sup> antigens, 118–119

## **X-Y**

Xg<sup>a</sup> blood group, 122

Xigris, 381–383, 394

Yt<sup>a</sup>/Yt<sup>b</sup> antigens, 117